HomeMBIO • NASDAQ
add
Mustang Bio Inc
Previous close
$1.25
Day range
$1.21 - $1.27
Year range
$0.89 - $21.95
Market cap
9.12M USD
Avg Volume
90.99K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 624.00K | -57.17% |
Net income | -468.00K | 66.81% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -624.00K | 55.62% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 18.98M | 438.55% |
Total assets | 19.36M | 169.16% |
Total liabilities | 9.59M | -39.49% |
Total equity | 9.77M | — |
Shares outstanding | 7.30M | — |
Price to book | 0.93 | — |
Return on assets | -9.63% | — |
Return on capital | -24.64% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -468.00K | 66.81% |
Cash from operations | -818.00K | 53.44% |
Cash from investing | 0.00 | — |
Cash from financing | 7.14M | 604.64% |
Net change in cash | 6.33M | 951.55% |
Free cash flow | -919.00K | 23.07% |
About
Mustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency. Wikipedia
Founded
2015
Headquarters
Website
Employees
6
